SCHEMBL4292592

SCHEMBL4292592

CCCC[Sn](CCCC)(CCCC)c1nnn(Cc2ccccc2)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.41
SLC9A1 P19634 1/20 0.41
CYP19A1 P11511 6/20 0.40
KDM4E B2RXH2 2/20 0.39
IDO1 P14902 1/20 0.39
LMNA P02545 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
CDC7 O00311 1/20 0.38
PLK4 O00444 1/20 0.38
MAPK13 O15264 1/20 0.38
PDPK1 O15530 1/20 0.38
DAPK3 O43293 1/20 0.38
DYRK3 O43781 1/20 0.38
JAK2 O60674 1/20 0.38
ROCK2 O75116 1/20 0.38
RPS6KA5 O75582 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKCG P05129 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16241084 0.89 CYP19A1 (0.35) GRM2SLC9A1CYP19A1KDM4EIDO1
SCHEMBL3669940 0.84 CYP19A1 (0.48) GRM2SLC9A1CYP19A1IDO1ALDH1A1
SCHEMBL4291497 0.84 GRM2 (0.39) GRM2SLC9A1CYP19A1KDM4EIDO1
SCHEMBL4292554 0.82 CDC7 (0.44) GRM2SLC9A1CYP19A1IDO1HPGD
SCHEMBL3667322 0.81 ROCK2 (0.43) GRM2SLC9A1CYP19A1KDM4EIDO1
SCHEMBL4295553 0.79 CDC7 (0.46) GRM2SLC9A1CYP19A1IDO1CDC7
SCHEMBL4707683 0.78 HSP90AA1 (0.35)
SCHEMBL4291234 0.78 SMN1; SMN2 (0.51) CYP19A1ALDH1A1HPGDTSHRKMT2A
SCHEMBL4297826 0.78 CDC7 (0.44) CYP19A1KDM4ELMNAALDH1A1CDC7
SCHEMBL4284826 0.78 KMT2A (0.48) GRM2SLC9A1CYP19A1KDM4EIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 GRM2 4237/4885SLC9A1 4045/4885CYP19A1 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.